Adding Darolutamide: New SOC for Metastatic Prostate Cancer Adding Darolutamide: New SOC for Metastatic Prostate Cancer
Darolutamide added onto ADT and docetaxel could be a new standard of care for men with metastatic hormone-sensitive prostate cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Hematology | Hormones | Prostate Cancer | Taxotere